The third most cited study was published by Buzdar et al. in Journal of Clinical Oncology (2005) with 941 citations, demonstrating that adding trastuzumab to neoadjuvant chemotherapy significantly increased pathologic complete response rates in HER2-positive operable breast cancer without causing clinical congestive heart failure, though cardiac ejection fraction reductions were observed. The gene discussed is ERBB2; the disease is breast carcinoma.